A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids

Hengrui Medicine logo

Hengrui Medicine

Status and phase

Enrolling
Phase 3
Phase 2

Conditions

Uterine Fibroids With Menorrhagia

Treatments

Drug: SHR7280 tablets
Drug: PlaceboSHR7280 tablets blank preparation

Study type

Interventional

Funder types

Industry

Identifiers

NCT05442827
SHR7280-301

Details and patient eligibility

About

Phase II:To explore the optimal effective dose of SHR7280 tablets in subjects with menorrhagia with uterine fibroids as a phase III treatment dose. Phase III:To evaluate the efficacy of the selected dose of SHR7280 compared with placebo in reducing menstrual bleeding in subjects with menorrhagic uterine fibroids in phase II studies.

Enrollment

357 estimated patients

Sex

Female

Ages

18 to 49 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • The informed consent has been signed and dated;
  • Non-menopausal women between the ages of 18 and 49 (including 18 and 49);
  • Single or multiple uterine fibroids were confirmed by ultrasound examination during screening, and the maximum diameter of at least one fibroid was ≥2 cm;
  • Heavy menstrual bleeding measured by the alkaline hematin method during screening;
  • 3 months before screening, the subject's menstrual cycle is 21-38 days, and the period is no more than 14 days;
  • The pregnancy test was negative on the day of screening visit and randomization;
  • Human papillomavirus (HPV) testing should be added for subjects who have cervical cytology at the time of screening visit and whose TCT results are atypical squamous cells (ASC-US) of uncertain significance, or who test negative for high-risk HPV.

Exclusion criteria

  • Excessive menstrual bleeding and anemia caused by other reasons;
  • A history of depression or clinically significant depression;
  • Have a history of drug abuse, drug dependence;
  • History of smoking and alcohol abuse within 3 months prior to screening;
  • A history of delivery, breastfeeding and miscarriage within 6 months prior to screening;
  • Patients who received myomectomy within 3 months before screening, and patients who received uterine artery embolization, or high intensity focused ultrasound (HIFU) ablation within 6 months before screening;
  • Patients who underwent endometrial resection within 1 year prior to screening;
  • Patients with severe infection (one organ or whole body infection caused by pathogenic microorganism, and failure or death of the organ or multiple organs caused by infection), severe trauma (ISS ≥16 points) or major surgery (grade III/IV surgery in Surgical Classification Catalogue) within 6 months prior to screening;
  • Previous clinical major systemic disease, endocrine or metabolic abnormalities;
  • Having past or current thromboembolic disease or having a risk factor for thromboembolic disease (stage 2 only);
  • Previous history of malignant tumors such as ovary, breast, uterus, liver, hypothalamus and pituitary gland;Known or suspected sex hormone-dependent malignancies;
  • Any pre-existing disease or symptom (e.g., chronic intestinal disease, Crohn's disease, ulcerative colitis) that may affect systemic functioning of the body and may affect absorption, excessive accumulation, metabolism, or change the excretion pattern of the test drug;
  • Persons with prior known serious mental illness or inability to understand the purpose, methods, etc. of the clinical trial, and who did not follow the study procedures;
  • Live (attenuated) vaccine (other than influenza vaccine) received within 1 month prior to screening or planned during the trial;
  • Other reasons that the investigator considered inappropriate for participation in the study.
  • Follicle-stimulating hormone (FSH) ≥25U/L during screening;
  • Hb < 6 g/dL during screening;
  • Moderate to severe liver impairment during screening, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin (unless Gilbert's diagnosis is known) ≥2.0 times the upper limit of the reference range;
  • During screening, endometrial biopsy should be performed if endometrial thickness > 18 mm is indicated by gynecological ultrasound or if the investigator deems it necessary. Endometrial histological abnormalities indicated by endometrial biopsy should be performed (only in the first stage).
  • Active pelvic inflammatory disease (PID) during screening;
  • QTcF≥450ms during screening;
  • Infectious disease screening resultshave clinical significance;
  • 6 months before enrollment, endometrial biopsy revealed significant endometrial histological abnormalities;If the subject has no sexual life history or the investigator determines that it is not necessary, the subject may be exempted (stage 2 only);
  • Two or more blood transfusions within 9 months prior to enrollment, or requiring transfusion therapy within 2 months prior to enrollment, or having any condition requiring immediate transfusion;
  • 1 month before admission, she used any drugs that inhibited or induced liver metabolism of drugs (liver drug enzyme inhibitors such as chloramphenicol, allopurinol,ketoconazole, fluoroquinolones, etc., and liver drug enzyme inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin sodium, rifamequine);
  • Participants in and enrolled in clinical trials of any drug or medical device within 3 months prior to enrollment, or who were still in the follow-up period of a clinical study or within 5 half-lives of the tested drug prior to screening, whichever is longer.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

357 participants in 3 patient groups, including a placebo group

Treatment group A: SHR7280 tablets
Experimental group
Treatment:
Drug: SHR7280 tablets
Treatment group B:SHR7280 tablets
Experimental group
Treatment:
Drug: SHR7280 tablets
Treatment group C:Intervention: Drug: PlaceboSHR7280 tablets blank preparation
Placebo Comparator group
Treatment:
Drug: PlaceboSHR7280 tablets blank preparation

Trial contacts and locations

1

Loading...

Central trial contact

Zhenyi Zhu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems